Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBehind the Wegovy Sales Story: Facts That Actually Affect Your Treatment
The biggest myth: high sales mean Wegovy is easy to get hold of
When Novo Nordisk releases quarterly results showing double-digit growth in Wegovy sales, the natural assumption is that supply must have caught up. In most cases, that assumption is wrong. Semaglutide demand has repeatedly exceeded production capacity since Wegovy launched in the UK. Throughout 2024 and into 2025, certain doses were periodically limited or unavailable from some suppliers, and pharmacies regularly had to manage patient expectations around the titration schedule.
If you want to understand the fuller picture of how those numbers are made up, our page on what Wegovy sales figures actually represent explains how revenue from dispatched wholesale stock can diverge sharply from what is available on a pharmacy shelf. A record quarter for Novo Nordisk can coincide with a shortage at the 1.7mg step for patients trying to titrate. If you have read headlines about surging Wegovy sales and assumed that means walking into any pharmacy and collecting any dose on the same day, the reality is more complicated than that.
The NHS semaglutide medicines page covers what the treatment involves, including the titration pathway, and is worth reading before you start. Supply position changes regularly, so it is worth confirming availability at the point of consultation.
What the 2025 sales growth actually reflects about clinical evidence
The commercial numbers are not without clinical grounding. Wegovy's sales trajectory is built on a substantial evidence base. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks in adults without diabetes on the 2.4mg maintenance dose, alongside lifestyle changes. That is the kind of result that drives prescriber confidence and patient demand simultaneously.
The medicine's profile has also expanded. In January 2026 the MHRA approved a higher 7.2mg maintenance dose, initially supplied as three 2.4mg pens per week, and a dedicated single-dose 7.2mg pen received approval on 14 April 2026 for adults with a BMI of 30 or above. Trials at this higher dose reported average weight loss of around 20.7% over 72 weeks, which narrows the gap with tirzepatide (Mounjaro) considerably. For a thorough look at how the treatment has developed and where it stands now, our guide to Wegovy in 2025 and the semaglutide treatment page lay out both options clearly.
None of this changes the basic legal position: semaglutide is a prescription-only medicine, and a prescriber has to assess whether it is right for you individually before any supply can take place.
What record Wegovy sales mean for pricing in 2025
High demand and constrained supply have an obvious effect on price. Private Wegovy costs have generally risen through 2024 and 2025 as both manufacturers adjusted list prices and private providers absorbed supply-chain costs. If you are comparing prices across clinics, our Wegovy pricing page gives an honest picture of what affects the cost and what a transparent price should include: consultation, prescription, clinical review, and delivery.
What is worth being clear about: the cheapest listing is not always the safest one. The MHRA has warned publicly and repeatedly about counterfeit weight-loss pens circulating online, including fake tirzepatide pens seized from an illicit manufacturing site in 2025. For a prescription medicine, the right question is not which seller quotes the lowest number, but whether the pharmacy is registered and the supply chain is licensed. You can check any online pharmacy on the GPhC register in under a minute. That small step is worth doing before you hand over any payment details.
NHS access versus private routes in a high-demand market
The surge in Wegovy sales has also made the gap between NHS and private access more visible. NICE recommends semaglutide for weight management (TA875) within specialist services, for a maximum of two years, for patients with a BMI of 35 or above and at least one weight-related condition, with lower thresholds for some ethnic backgrounds. In practice, specialist NHS weight management services carry long waiting lists in most parts of England. A GP cannot simply write a Wegovy prescription the way they might for a routine antibiotic.
For people who do not meet the NHS criteria or do not want to wait, a regulated private pharmacy is the alternative. Our page covering how semaglutide sales break down across NHS and private routes gives useful context on where most prescriptions are currently coming from and what that means for access, and if you want a closer look at how volumes shifted across the year, our breakdown of semaglutide sales in 2024 sets out the trends in detail. Our prescribers review every consultation themselves; if you have questions before starting, the FAQ page covers most of what people ask first.
Sales charts tell one story. Your individual health picture tells another. If semaglutide is something you are seriously considering, the only way to find out whether it is clinically appropriate for you is to speak to a prescriber. Start your free consultation and a GPhC-registered prescriber will review your details the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.